PepGen(US:PEPG) Prnewswireยท2025-07-03 11:30Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of misleading statements regarding the effectiveness and safety of its drug PGN-EDO51, which has led to significant stock price declines and a federal securities class action [2][4]. Group 1: Allegations and Legal Actions - The complaint against PepGen alleges violations of federal securities laws, including false statements about the effectiveness and safety of PGN-EDO51 and deficiencies in the CONNECT2 study [4]. - Investors who purchased PepGen securities between March 7, 2024, and March 3, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against PepGen is August 11, 2025 [2]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a 32.69% drop in stock price [5][6]. - Following a clinical hold notice from the FDA on December 16, 2024, due to safety concerns, PepGen's stock fell by 3.63% [7][8]. - A subsequent update on January 29, 2025, regarding safety concerns in the CONNECT1 study led to a further 21.74% decline in stock price [9][10]. - On March 4, 2025, PepGen announced a voluntary pause of the CONNECT2 study, resulting in an 18.86% drop in stock price [10]. - On May 28, 2025, PepGen disclosed that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].